BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pasritamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pasritamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07319871-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:Pasritamig: Phase 1 readout est. (NCT07319871)
DESCRIPTION:Pasritamig\, phase 1.\nStudy: A Study of Pasritamig (JNJ-782783
 43) in Combination With JNJ-86974680 for Treatment of Prostate Cancer\nEst
 imated primary completion: 7 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07319871
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05818683-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pasritamig: Phase 1 readout est. (NCT05818683)
DESCRIPTION:Pasritamig\, phase 1.\nStudy: A Study of Pasritamig (JNJ-782783
 43) in Combination With Other Agents for Metastatic Prostate Cancer\nEstim
 ated primary completion: 31 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05818683
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225946-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07225946)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With Docetaxel Versus Docetaxel in 
 Participants With Metastatic Castration-Resistant Prostate Cancer\nEstimat
 ed primary completion: 19 November 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07225946
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07945821-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pasritamig: Phase 1/2 readout est. (NCT07945821)
DESCRIPTION:Pasritamig\, phase 1/2.\nStudy: A Study of Tagmokitug in Combin
 ation With Other Treatments in Participants With Advanced or Metastatic So
 lid Tumors\nEstimated primary completion: August 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07945821
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164443-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20280818
DTEND;VALUE=DATE:20280819
SUMMARY:Pasritamig: Phase 3 readout est. (NCT07164443)
DESCRIPTION:Pasritamig\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Study of Pasritamig With or Without JNJ-87189401 Versus
  Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mC
 RPC)\nEstimated primary completion: 18 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07164443
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860255-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pasritamig: Phase 1 readout est. (NCT07860255)
DESCRIPTION:Pasritamig\, phase 1.\nStudy: Testing Pasritamig Before Surgery
  for the Treatment of Localized Prostate Cancer\nEstimated primary complet
 ion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pasritamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07860255
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871435-11218@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pasritamig: Phase 1/2 readout est. (NCT07871435)
DESCRIPTION:Pasritamig\, phase 1/2\, Metastatic Castration-Resistant Prosta
 te Cancer.\nStudy: GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasrita
 mig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRP
 C) (JET-201)\nEstimated primary completion: 31 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pasritamig#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07871435
URL:https://assetmemo.bio/drug/pasritamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
